Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Protein kinase inhibitors to treat non-small-cell lung cancer

19 Apr 2014

Abstract excerpt

INTRODUCTION: Activating mutations of the EGFR and rearrangement of anaplastic lymphoma kinase (ALK) best illustrate the therapeutic relevance of molecular characterization in NSCLC patients. AREAS COVERED: For this review article, all published data on the most relevant Phase III trials with tyrosine kinase inhibitors (TKIs) for the treatment of NSCLC were collected and analyzed. EXPERT OPINION: Eight Phase III...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24745764
DOI: 10.1517/14656566.2014.909412

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Protein kinase inhibitors to treat non-small-cell lung cancerPMID 24745764Read ↗

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.Semantic proximity Read ↗

Pharmacotherapy targeting the EGFR oncogene in NSCLC.Semantic proximity Read ↗

Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.Semantic proximity Read ↗

Targeted therapies and immunotherapy in non-small-cell lung cancerSemantic proximity Read ↗

Emerging protein kinase inhibitors for non-small cell lung cancerSemantic proximity Read ↗

Molecular therapeutic targets in non-small cell lung cancer.Semantic proximity Read ↗

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Semantic proximity Read ↗

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.Semantic proximity Read ↗

New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.